Certara Reports Second Quarter 2025 Financial Results
RADNOR, PA— 2025 年 8 月 6 日-- Certara, Inc. （纳斯达克股票代码：CERT), a global leader in model-informed drug development,…
Certara2025 年 8 月 6 日
De-risking DDI Management during Clinical Trials: Introducing DIDB’s Concomitant Meds Navigator
Watch the on-demand presentation covering how the DIDB® Concomitant Meds Navigator empowers clinical development teams…
Certara2025 年 8 月 5 日
Model-based meta-analysis (MBMA) at GSK: Real-world impact on strategy and trials
GSK shares real-world case studies on how Model-Based Meta-Analysis (MBMA) supports dose selection, virtual control…
Certara2025 年 7 月 31 日
MIDD Strategies for Preclinical and Clinical Translation: A Collaboration Between Clinical Pharmacologists and Modeling Disciplines
Learn how clinical pharmacologists and modeling experts collaborate to improve preclinical-to-clinical translation.
Certara2025 年 7 月 29 日
Three Approaches to AI Adoption in Regulatory Writing
Certara experts discuss AI adoption in medical writing: learn practical models, GenAI & SCA integration,…
Certara2025 年 7 月 23 日
How to Create a Data Validation Plan in Clinical Trials
Download our guide to creating a data validation plan in clinical trials, the ultimate blueprint…
Certara2025 年 7 月 21 日
The reference-scaled average bioequivalence (RSABE) approach
We examine the Reference-scaled Average Bioequivalence (RSABE) approach for generic drug development and how it…
Ana Henry2025 年 7 月 1 日
5 clinical development challenges model-based meta-analysis (MBMA) helps address
2025 年 6 月 30 日 Drug development is increasingly defined by its complexity. Teams must navigate rising…
Certara2025 年 6 月 30 日
